226-240 of 305
Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer
MinuteCE®Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer
Susana Campos, MD, MPH
Ritu Salani, MD, MBA
Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
MinuteCE®Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
Ritu Salani, MD, MBA
Nicoletta Colombo, MD
Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
MinuteCE®Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
Susana Campos, MD, MPH
Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
MinuteCE®Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
Nicoletta Colombo, MD
Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances
MinuteCE®Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances
Susana Campos, MD, MPH
Nicoletta Colombo, MD
Pasi Antero Jänne, MD, PhD
Helena Yu, MD
- advertisement
Case Application: Patients With EGFRm Resistance Post TKI and Platinum Chemotherapy
MinuteCE®Case Application: Patients With EGFRm Resistance Post TKI and Platinum Chemotherapy
Pasi Antero Jänne, MD, PhD
Helena Yu, MD
Case Application: Adverse Event Management of Patients With EGFRm Resistance Treated With Novel HER3-Directed ADCs
MinuteCE®Case Application: Adverse Event Management of Patients With EGFRm Resistance Treated With Novel HER3-Directed ADCs
Helena Yu, MD
Pasi Antero Jänne, MD, PhD
Expert Peer Discussion: Integrating Novel HER3-Directed ADCs Upon Disease Progression Following EGFR TKI and Platinum Chemotherapy
MinuteCE®Expert Peer Discussion: Integrating Novel HER3-Directed ADCs Upon Disease Progression Following EGFR TKI and Platinum Chemotherapy
Pasi Antero Jänne, MD, PhD
Helena Yu, MD
Biologic Rationale for Targeting HER3 and Role in EGFR Resistance
MinuteCE®Biologic Rationale for Targeting HER3 and Role in EGFR Resistance
Pasi Antero Jänne, MD, PhD
Overcoming EGFR Resistance With HER3-Directed ADCs
MinuteCE®Overcoming EGFR Resistance With HER3-Directed ADCs
Helena Yu, MD
Interprofessional Monitoring and Management of AEs With HER3-Directed ADCs
MinuteCE®Interprofessional Monitoring and Management of AEs With HER3-Directed ADCs
Helena Yu, MD
Pasi Antero Jänne, MD, PhD
- advertisement
Differentiating Biomarker-Driven First-Line Treatment Strategies in Metastatic Gastric/GEJ Cancers
CME/CE Broadcast ReplayDifferentiating Biomarker-Driven First-Line Treatment Strategies in Metastatic Gastric/GEJ Cancers
Nataliya Uboha, MD, PhD
Luis Paz-Ares, MD, PhD
Helena Yu, MD
Matthew Gubens, MD, MS
Application of guidelines-recommended broad molecular profiling to patients with NSCLC
MinuteCE®Application of guidelines-recommended broad molecular profiling to patients with NSCLC
Luis Paz-Ares, MD, PhD
Helena Yu, MD
Matthew Gubens, MD, MS
